Statistical properties of time to first relapse as an endpoint in multiple sclerosis clinical trials

被引：0
|
作者：
Signori, A.
Siri, P.
Sormani, M. P.
机构：
[1] Univ Genoa, Genoa, Italy
[2] Politecn Torino, Turin, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：29 / 30
页数：2
相关论文
共 50 条
  • [1] Time to first relapse as an endpoint in multiple sclerosis clinical trials
    Sormani, M. P.
    Signori, A.
    Siri, P.
    De Stefano, N.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (04) : 466 - 474
  • [2] Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
    Kitley, J.
    Leite, M. I.
    Elsone, L.
    Jacob, A.
    Palace, J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 331 - 332
  • [3] Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials
    Kitley, Joanna
    Leite, M. Isabel
    Elsone, Liene
    Jacob, Anu
    Palace, Jackie
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (05): : 589 - U118
  • [4] Relapse recovery The forgotten variable in multiple sclerosis clinical trials
    Kantarci, Orhun H.
    Zeydan, Burcu
    Atkinson, Elizabeth J.
    Conway, Brittani L.
    Castrillo-Viguera, Carmen
    Rodriguez, Moses
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (02):
  • [5] Statistical Testing of Single and Multiple Endpoint Hypotheses in Group Sequential Clinical Trials
    Huque, Mohammad
    Mushti, Sirisha
    Alosh, Mohamed
    [J]. BIOPHARMACEUTICAL APPLIED STATISTICS SYMPOSIUM, VOL 3: PHARMACEUTICAL APPLICATIONS, 2018, : 119 - 149
  • [6] Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis
    Cover, KS
    Petkau, J
    Paty, DW
    [J]. NEUROLOGY, 1999, 52 (02) : 433 - 434
  • [7] Recent trends in the use of wearable sensors to capture endpoint data in multiple sclerosis clinical trials
    Khurana, Laura
    Hughes, Lindsay
    Horak, Fay
    Sowalsky, Kristen
    [J]. QUALITY OF LIFE RESEARCH, 2021, 30 (SUPPL 1) : S127 - S128
  • [8] Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?
    Rossman, Ian T.
    Cohen, Jeffrey A.
    [J]. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (05) : 489 - 491
  • [9] An overview of statistical methods for multiple failure time data in clinical trials
    Wei, LJ
    Glidden, DV
    [J]. STATISTICS IN MEDICINE, 1997, 16 (08) : 833 - 839
  • [10] Clinical trials in multiple sclerosis: milestones
    Zhang, Yinan
    Salter, Amber
    Cutter, Gary
    Stuve, Olaf
    [J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
12345